Switch to
View more

Wockhardt Ltd

WOCKPHARMA
Health CarePharmaceuticals
SmallcapWith a market cap of ₹3,377 cr, stock is ranked 604
Moderate RiskStock is 2.62x as volatile as Nifty
263.0028.55 (+12.18%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹3,377 cr, stock is ranked 604
Moderate RiskStock is 2.62x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
-15.53
PB RatioPB Ratio
0.90
Dividend YieldDiv. Yield
Sector PESector PE
34.62
Sector PBSector PB
4.37
Sector Div YldSctr Div Yld
0.92%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Wockhardt Limited manufactures and markets pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines.

Brands

Wockhardt

Research-based healthcare enterprise focused on pharmaceuticals and biotechnology

Investor PresentationView older 

Mar 8, 2022

PDF
View Older Presentations

Brands

Wockhardt

Research-based healthcare enterprise focused on pharmaceuticals and biotechnology

Financial TrendFinancial statements 

20192020202120223.682.983.833.25-0.19-0.070.69-0.24
Revenue
Profit
Loss
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 1.39%

High Pledged Promoter Holding
Lower pledged promoter holdings is considered better

A significant proportion of promoter holdings is pledged

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Press Release 
Announced OnAug 16, 2022

Wockhardt Limited has informed the Exchange about press release dated 16-Aug-2022 titled Wockhardt announces successful initiation of Global Phase 3 Clinical Study of its novel antibiotic WCK 5222 | Download

Wockhardt Limited has informed the Exchange about press release dated 16-Aug-2022 titled Wockhardt announces successful initiation of Global Phase 3 Clinical Study of its novel antibiotic WCK 5222 | Download

General updates 
Announced OnAug 12, 2022

Pursuant to Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, we hereby confirm that there has been no deviation in the utilisation of Issue proceeds from the objects as stated in the Letter of Offer for Rights Issue dated 4th March 2022. | Download

Pursuant to Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, we hereby confirm that there has been no deviation in the utilisation of Issue proceeds from the objects as stated in the Letter of Offer for Rights Issue dated 4th March 2022. | Download

Cash Dividend 
Ex. DateNov 17, 2016

Interim • Div/Share: ₹ 10

See all events